SLC5A2 and diabetes mellitus: A recent large-scale meta-analysis by Usman et al. [11] evaluated the effects of SGLT2 inhibitors on cardiovascular death and heart failure events in diverse cardiometabolic populations, including those with diabetes, chronic kidney disease, and atherosclerotic disease.